Loading clinical trials...
Loading clinical trials...
A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis
Conditions
Interventions
PRM-151 (Zinpentraxin Alfa)
Placebo
Locations
360
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Banner University Medical Center Phoenix; Main Pharmacy
Phoenix, Arizona, United States
Lovelace Scientific Resources, Inc.
Phoenix, Arizona, United States
UC Irvine Medical Center
Orange, California, United States
Stanford Hospital and Clinics
Palo Alto, California, United States
University of California Davis
Sacramento, California, United States
Start Date
March 19, 2021
Primary Completion Date
February 10, 2023
Completion Date
February 10, 2023
Last Updated
April 18, 2024
NCT06238622
NCT07299695
NCT07466420
NCT06241560
NCT07407543
NCT05989698
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions